Thiopurine s-methyltransferase deficiency is an inherited condition that changes how the body breaks down thiopurine medicines. Many living with thiopurine s-methyltransferase deficiency feel well until they take one of these drugs, and then they may develop serious side effects such as severe bone marrow suppression, infections, mouth sores, or unusual tiredness. It may help to know that doctors have studied this condition for decades, and genetic testing for thiopurine s-methyltransferase deficiency can help guide safer dosing. This condition is lifelong and is often recognized before or during treatment in children or adults who need thiopurine medicines. It is not usually life-threatening on its own, but reactions can become dangerous without dose adjustment, close blood test monitoring, or use of a different medicine.
How many people live with Thiopurine s-methyltransferase deficiency?
Widely used estimates suggest that about 1 in 300 people have thiopurine S-methyltransferase deficiency, meaning they have very little ability to break down certain medicines; based on current population totals, that suggests roughly 27 million people worldwide (FDA, 2020; United Nations, 2024). Using the same often-cited rate, that suggests about 1.1 million people in the United States (FDA, 2020; U.S. Census Bureau, 2024), although the exact number can vary by ancestry and by whether testing is based on genes or enzyme activity.
Overview
Thiopurine s-methyltransferase deficiencySymptoms
Thiopurine S-methyltransferase deficiency usually causes no everyday signs on its own. The main risk appears after thiopurine medicines, when people with Thiopurine S-methyltransferase deficiency can develop severe low blood counts, infections, mouth sores, unusual bruising, and extreme tiredness.
Outlook and prognosis
Thiopurine s-methyltransferase deficiency does not usually affect daily health on its own. The main concern is a much higher risk of severe side effects from thiopurine medicines, but genetic testing and dose changes usually allow safer treatment.
Causes and risk factors
Thiopurine S-methyltransferase deficiency is caused by inherited changes in the TPMT gene, usually passed down from one or both parents, though new changes can happen. Risk is highest with a family history, and problems often appear after thiopurine medicines are used.
Genetic influences
Genetics are central to thiopurine S-methyltransferase deficiency. Changes in the TPMT gene largely determine how much enzyme your body makes, so inherited variants strongly affect who develops it and how they respond to thiopurine medicines.
Diagnosis
Thiopurine S-methyltransferase deficiency is usually diagnosed with blood tests that measure enzyme activity or look for changes in the TPMT gene. The genetic diagnosis of Thiopurine S-methyltransferase deficiency may be done before starting thiopurine medicines.
Treatment and drugs
Thiopurine s-methyltransferase deficiency mainly affects how certain medicines are used. Many with thiopurine s-methyltransferase deficiency need much lower doses of azathioprine, mercaptopurine, or thioguanine, or different drugs altogether. Regular blood tests help keep treatment safe.
Symptoms
Most people with thiopurine S-methyltransferase deficiency feel completely well in daily life and may not know they have it. For many people with thiopurine S-methyltransferase deficiency, problems appear only after starting thiopurine medicines such as azathioprine, mercaptopurine, or thioguanine. The early features of thiopurine S-methyltransferase deficiency are often easy to miss because the body clears these drugs too slowly, letting them build up. This can lead to harmful side effects, especially very low blood counts, and the risk is highest in people with little or no TPMT enzyme activity.
Without thiopurine medicine exposure, most people with TPMT deficiency do not have noticeable physical features. It is often found through a medication safety test rather than because someone feels unwell.
After starting thiopurine treatment, the bone marrow can slow down too much and make fewer blood cells. People may feel unusually tired, weak, or short of breath, and blood tests may show the problem before symptoms become obvious.
A very low white blood cell count can make infections more likely and harder to fight off. Fever, chills, a sore throat, or mouth ulcers after starting azathioprine or mercaptopurine can be warning signs.
Low platelets can lead to easy bruising, bleeding gums, nosebleeds, or tiny red or purple spots on the skin. Some may also notice that bleeding takes longer than usual to stop.
How people usually first notice Thiopurine s-methyltransferase deficiency?
Thiopurine S-methyltransferase deficiency is often silent for years, so many people do not know they have it until they start a thiopurine medicine such as azathioprine, mercaptopurine, or thioguanine. The first signs of Thiopurine S-methyltransferase deficiency are usually unusually strong side effects after starting one of these drugs, especially a sharp drop in blood counts that can lead to frequent infections, easy bruising or bleeding, extreme tiredness, or mouth sores. In many cases, though, how Thiopurine S-methyltransferase deficiency is first noticed is through a genetic test or enzyme test ordered before treatment, which helps doctors lower the dose or choose a different medicine and prevent these problems.
Types of Thiopurine s-methyltransferase deficiency
No distinct types of Thiopurine s-methyltransferase deficiency are widely recognized.
Can I slow down the onset of symptoms?
Usually no: there is no good evidence that diet, exercise, sleep, or supplements can delay symptoms of TPMT deficiency, because problems usually start only if someone takes certain medicines that their body cannot break down well. The most effective step is medical screening before treatment: well-established guidelines recommend checking for TPMT deficiency before or during use of thiopurine medicines so the dose can be lowered or a different medicine can be chosen, which can reduce the risk of serious side effects but does not change the underlying condition. This cannot guarantee that problems will never happen, but finding it early can make treatment much safer.
What genetics can tell you about symptoms
Yes. In thiopurine S-methyltransferase deficiency, changes in the TPMT gene mainly help predict how your body handles thiopurine medicines, so they can strongly affect whether serious treatment-related symptoms appear, how severe they are, and how soon they start after treatment begins. Many people with this genetic change feel well until they take one of these medicines, but some variants cause a bigger drop in enzyme activity than others, which raises the risk of problems such as severe bone marrow suppression, infections, easy bruising, or mouth sores.
Causes and risk factors
Some people only learn they have thiopurine S-methyltransferase deficiency when a standard dose of azathioprine, mercaptopurine, or thioguanine causes unusually strong side effects. The cause is a change in the TPMT gene. It is usually inherited from one or both parents, and it leaves the body with low or absent TPMT enzyme activity. People with two changed copies have the highest risk of severe drops in blood cell counts, and risk also rises with one changed copy, higher thiopurine doses, certain other medicines, or existing liver or bone marrow problems. Genetic testing can sometimes clarify your personal risk of severe side effects from thiopurine drugs, and lifestyle habits do not usually cause the deficiency itself.
What are the most common causes or risk factors?
Thiopurine s-methyltransferase deficiency is almost always inherited, not caused by lifestyle or anything you did. It happens when someone is born with a change in the TPMT gene, especially if they inherit two nonworking copies from their parents; having a family history raises the chance, and some of these gene changes are more common in certain ancestry groups. The main non-genetic risk factor for serious problems is taking thiopurine medicines, such as azathioprine, mercaptopurine, or thioguanine, because people with this condition break down these drugs too slowly.
Environmental and biological risk factors
People often look for risk factors for thiopurine S-methyltransferase deficiency, but unlike many conditions, there are no proven environmental causes. Some risks are carried inside the body, others come from the world around us. For thiopurine S-methyltransferase deficiency, the known influences mainly reflect background biology rather than day-to-day exposures.
No environmental exposure has been shown to cause thiopurine S-methyltransferase deficiency. It is not known to result from diet, stress, infections, or pollution.
This deficiency is found in many populations, but how often it occurs can vary between ethnic and regional groups. These differences reflect underlying biology, not something someone did or was exposed to.
Thiopurine S-methyltransferase deficiency can run in families, so it may be more likely if close relatives are known to have it. In practice, this is why family history can prompt testing before certain medicines are used.
Genetic risk factors
Thiopurine s-methyltransferase deficiency usually happens because of inherited changes in the TPMT gene, which helps the body process certain medicines. Some risk factors are inherited through our genes. The biggest genetic risk is inheriting one or two reduced-function TPMT copies from your parents, and the chance is higher when the change already runs in your family. When people ask about the genetic causes of thiopurine s-methyltransferase deficiency, this gene is the main place doctors look.
TPMT gene variants: Most cases are caused by inherited changes in the TPMT gene. These changes lower how much working TPMT enzyme the body makes.
Two altered copies: Inheriting a reduced-function TPMT copy from each parent creates the highest chance of severe TPMT deficiency. Many people with two nonworking copies make very little or no TPMT enzyme.
One altered copy: Having one reduced-function TPMT copy and one usual copy often leads to intermediate enzyme activity instead of complete deficiency. This still reflects a genetic risk because TPMT function can be lower than expected.
Family history: A close relative with TPMT deficiency or a known TPMT gene change makes the same inherited pattern more likely in your family. This is often a strong clue that other relatives may also carry the change.
Ancestry patterns: Some TPMT variants are more common in certain population groups than in others. This affects how often thiopurine s-methyltransferase deficiency is seen in different communities, although it can occur in any ancestry.
Lifestyle risk factors
Thiopurine s-methyltransferase deficiency is inherited, so lifestyle habits do not cause it. However, how lifestyle affects Thiopurine s-methyltransferase deficiency can matter a great deal when a person takes thiopurine medicines, because some habits can raise the chance of serious side effects or make complications harder to detect. The main lifestyle-related issues involve alcohol use, infection exposure, sun habits, smoking, and nutrition or supplement choices during treatment.
Heavy or regular alcohol intake can add liver stress on top of the liver toxicity risk that thiopurine medicines already carry in people with TPMT deficiency. Limiting alcohol may lower the chance that abnormal liver tests or liver injury become more severe.
Crowded settings, poor hand hygiene, and close contact with people who are ill can matter more if thiopurine treatment lowers white blood cell counts. Reducing infection exposure can help prevent complications when TPMT deficiency increases the risk of treatment-related myelosuppression.
People taking thiopurines may have a higher risk of sun damage and some skin cancers, so frequent tanning or unprotected sun exposure can be especially harmful. Consistent sunscreen use, protective clothing, and avoiding tanning beds can reduce this added treatment risk.
Smoking can worsen inflammation, impair healing, and increase overall treatment burden in conditions commonly managed with thiopurines, such as inflammatory bowel disease. In someone with TPMT deficiency, that can complicate disease control and make medication-related problems harder to manage.
Risk prevention
For people with Thiopurine S-methyltransferase deficiency, the main goal is not preventing the condition itself, because it is an inherited trait present from birth. Prevention is really about avoiding serious side effects from certain medicines, especially thiopurine drugs such as azathioprine, mercaptopurine, and thioguanine. Many living with Thiopurine S-methyltransferase deficiency can stay safer when the condition is identified before treatment starts and medicines are adjusted carefully. Prevention can mean both medical steps, like genetic testing, and lifestyle steps, like keeping an up-to-date medication record.
Testing for Thiopurine S-methyltransferase deficiency before starting thiopurine medicine can greatly lower the risk of severe side effects. This helps doctors choose a safer dose or a different treatment from the start.
If you have Thiopurine S-methyltransferase deficiency, standard thiopurine doses may be too high for your body to handle safely. Lower doses or non-thiopurine options can help prevent dangerous drops in blood counts.
Regular blood tests are an important way to prevent complications in people with Thiopurine S-methyltransferase deficiency. They can catch early signs of bone marrow suppression, liver injury, or infection risk before symptoms become severe.
Make sure every prescriber and pharmacist knows about Thiopurine S-methyltransferase deficiency before new medicines are started. This can help avoid unsafe prescribing and reduce the chance of harmful drug combinations or duplicate thiopurine treatment.
Can you prevent Thiopurine s-methyltransferase deficiency?
No, you cannot prevent thiopurine S-methyltransferase deficiency itself, because it is an inherited trait you are born with. What you often can prevent, or greatly lower, are the serious side effects it can cause when certain medicines are used, by testing before treatment and then lowering the dose or choosing a different drug if needed. This matters for medicines such as azathioprine, mercaptopurine, and thioguanine, which some people with this condition cannot break down safely.
Transmission
Thiopurine S-methyltransferase deficiency is not infectious, so it does not spread through everyday contact, sex, food, or the air. Instead, the genetic transmission of thiopurine S-methyltransferase deficiency happens through inherited changes in the TPMT gene.
Most people with true thiopurine S-methyltransferase deficiency inherit one changed copy of the gene from each parent. If someone inherits only one changed copy, they often still make some of the enzyme, but at a lower level, and rarely a new genetic change can happen for the first time in a child.
When to test your genes
Genetic testing for TPMT is most useful before starting thiopurine medicines such as azathioprine, mercaptopurine, or thioguanine. It does not screen for disease early; instead, it helps customize dosing and can prevent dangerous bone marrow suppression, a severe drop in blood cells.
Diagnosis
Thiopurine S-methyltransferase deficiency is usually found when someone is about to start, or has had an unexpected reaction to, a thiopurine medicine such as azathioprine, mercaptopurine, or thioguanine. For many, the first step comes when routine planning before treatment shows a higher risk of severe side effects, especially a dangerous drop in blood counts. The diagnosis of thiopurine S-methyltransferase deficiency is confirmed with a blood test that checks either how well the enzyme works or which TPMT gene changes are present.
Doctors review which thiopurine drug is being considered or has already been used, and whether there has been unusual toxicity. This helps connect low TPMT activity with a real treatment risk rather than a general illness.
A complete blood count can show low white blood cells, anemia, or low platelets if thiopurines have already caused bone marrow suppression. These findings do not prove TPMT deficiency on their own, but they can raise concern and guide urgent follow-up.
A blood test can measure TPMT enzyme activity, usually from red blood cells. Very low or absent activity strongly suggests deficiency, while intermediate activity points to a partial deficiency that can still affect dosing.
Genetic tests look for changes in the TPMT gene that reduce how well the enzyme works. This can confirm the genetic diagnosis of thiopurine S-methyltransferase deficiency and may be especially useful before treatment begins.
How is Thiopurine s-methyltransferase deficiency diagnosed?
Thiopurine s-methyltransferase deficiency is usually found with a blood test that checks how well the TPMT body chemical is working, often before someone starts thiopurine medicines such as azathioprine, mercaptopurine, or thioguanine. Doctors may also use a genetic test to look for changes in the TPMT gene that can make this body chemical work poorly or not at all. Blood counts and any strong reaction to these medicines can also help confirm the diagnosis and guide safer dosing.
Stages of Thiopurine s-methyltransferase deficiency
Thiopurine s-methyltransferase deficiency does not have defined progression stages. This is because it is an inherited difference in how the body breaks down certain medicines, rather than an illness that steadily gets worse over time. Many people feel reassured knowing what their tests can—and can’t—show. In practice, thiopurine s-methyltransferase deficiency is usually found with a blood test or genetic test before starting thiopurine medicines, and monitoring then focuses on how safely your body handles treatment, including blood counts and dose adjustments.
Outlook and prognosis
With appropriate testing and dose adjustment before starting thiopurine medicines, the outlook for people with thiopurine S-methyltransferase deficiency is generally excellent. The main risk is not from the deficiency itself but from severe drug toxicity, especially profound bone marrow suppression, infections, liver injury, and other complications if standard doses of azathioprine, mercaptopurine, or thioguanine are given. When the condition is recognized early and prescribing is guided by TPMT activity or genetic results, many people can still be treated safely with lower doses or alternative medications. Mortality is uncommon when the deficiency is identified and managed properly, but untreated or unrecognized cases exposed to usual thiopurine doses can rarely lead to life-threatening complications and death. Long-term prognosis therefore depends mostly on awareness, careful medication selection, and close blood count monitoring during treatment.
Long-term effects
For many people, thiopurine s-methyltransferase deficiency does not cause day-to-day health problems on its own. The main long-term concern appears when certain medicines, especially thiopurines, are used, because the body may break them down too slowly and drug levels can build up. Long-term effects vary widely, from no lasting harm to serious complications if severe toxicity is not recognized quickly.
Thiopurine s-methyltransferase deficiency usually does not cause ongoing health problems unless a thiopurine medicine is taken. Many living with this condition feel completely well between treatments and may never notice any effects in daily life.
The most important long-term effect is severe lowering of blood cell production after thiopurine exposure. This can last for weeks and, in some cases, may require hospital care, transfusions, or other intensive treatment before the bone marrow recovers.
When white blood cells drop very low, the risk of serious infections rises sharply. Some may find that infections become harder to fight and can lead to prolonged recovery or life-threatening illness.
Low red blood cells can cause lasting fatigue, weakness, and shortness of breath during recovery, while low platelets can increase bruising or bleeding. These are among the early symptoms of thiopurine s-methyltransferase deficiency after thiopurine treatment and can sometimes take time to fully resolve.
How is it to live with Thiopurine s-methyltransferase deficiency?
For most people, thiopurine S-methyltransferase deficiency does not affect daily life at all until a thiopurine medicine is prescribed, such as azathioprine, mercaptopurine, or thioguanine. The main impact is the need for extra caution with medication choices and dosing, because standard doses can build up in the body and cause serious side effects, especially dangerous drops in blood cells, so many living with this condition need genetic testing on record and careful blood test monitoring if these drugs are ever used. It can also matter for those around you: family members may share the same genetic change, and caregivers or clinicians need to know about it so treatment is safer from the start.
Treatment and drugs
Thiopurine s-methyltransferase deficiency does not usually need treatment on its own, but it matters a great deal if you need certain medicines such as azathioprine, mercaptopurine, or thioguanine. People with Thiopurine s-methyltransferase deficiency break down these drugs more slowly, so standard doses can build up and cause serious side effects, especially a sharp drop in blood cells. When treatment is tailored to your genes, it’s often called personalized medicine, and for many living with Thiopurine s-methyltransferase deficiency this usually means a much lower starting dose, very close blood test monitoring, or choosing a different medicine altogether. If you are starting one of these drugs, ask about genetic testing or enzyme testing first, because early planning can help prevent dangerous problems such as infections, unusual bruising, or severe mouth sores.
Can you cure Thiopurine s-methyltransferase deficiency?
No, thiopurine S-methyltransferase deficiency cannot be cured, because it is an inherited difference in how your body handles certain medicines. The good news is that it can usually be managed very well by testing for it before treatment, avoiding these drugs when needed, or using much lower doses with close blood test monitoring to help prevent serious side effects.
Non-drug treatment
Thiopurine s-methyltransferase deficiency usually affects daily life when a person needs certain medicines, such as azathioprine, mercaptopurine, or thioguanine. The main non-drug approach is careful planning so those medicines are avoided or used only with very close specialist guidance, because the body may not break them down safely. Managing this condition often means working with your care team before starting any new prescription, especially if you have inflammatory bowel disease, leukemia, or an autoimmune condition. There is no lifestyle change that restores the missing enzyme, but education, testing, and monitoring can greatly lower risk.
A full medication review helps make sure thiopurine drugs are flagged before treatment starts. This is one of the most important safety steps for people with thiopurine s-methyltransferase deficiency.
Genetic counseling can help families understand how thiopurine s-methyltransferase deficiency is inherited and what test results may mean for relatives. It can be especially useful when parents, siblings, or children may also need these medicines in the future.
Regular blood tests can catch early signs of bone marrow suppression before serious infection or bleeding develops. This matters most if thiopurines must still be used in a reduced dose under specialist care.
Clear education helps you recognize warning signs such as unusual bruising, mouth sores, fever, or extreme tiredness. Knowing these early symptoms of thiopurine s-methyltransferase deficiency treatment problems can help you seek care quickly.
Your genes may have an impact on how drugs work for you
People living with thiopurine S-methyltransferase deficiency have an inherited change that makes it hard for their body to break down certain medicines, especially thiopurine drugs such as azathioprine, mercaptopurine, and thioguanine. This means a usual dose can build up too much in the body and cause serious side effects, like a dangerous drop in blood cells, infections, mouth sores, or severe tiredness, while a lower dose may work more safely. This is a well-known example of pharmacogenomics, meaning your genes can help doctors choose the safest dose or decide whether a different medicine would be better.
Pharmacological treatments
There is no medication that fixes thiopurine s-methyltransferase deficiency itself. Instead, treatment focuses on choosing thiopurine medicines very carefully, because standard doses can build up in the body and cause serious side effects, especially severe bone marrow suppression. The main drugs affected are azathioprine, mercaptopurine, and thioguanine. Not everyone responds to the same medication in the same way, so many living with thiopurine s-methyltransferase deficiency need major dose reductions or a different medicine altogether.
There is no approved drug that restores TPMT enzyme activity in thiopurine s-methyltransferase deficiency. For many, this can mean the safest plan is to avoid certain thiopurines or use much lower doses with close blood test monitoring.
Azathioprine can be used in some people with thiopurine s-methyltransferase deficiency, but the dose often needs to be reduced a lot, and some may need to avoid it completely. This helps lower the risk of dangerous drops in white blood cells, infections, mouth sores, and liver irritation.
Mercaptopurine is another thiopurine that often needs a major dose reduction in TPMT deficiency, especially in people with very low or absent enzyme activity. When people search for safe azathioprine and mercaptopurine dosing in TPMT deficiency, the key point is that treatment should be individualized and guided by regular blood counts.
Thioguanine is also affected by low TPMT activity and can cause severe toxicity if usual doses are given. Because of this, doctors may use a much smaller dose or choose a non-thiopurine alternative depending on the condition being treated.
Genetic influences
For people who need medicines such as azathioprine or mercaptopurine, genetics can make a major difference in how safely the body handles the drug. Thiopurine s-methyltransferase deficiency is caused by inherited changes in the TPMT gene, which controls an enzyme that helps break down these medicines. A change in a gene can sometimes affect health, and in this case it can leave the enzyme working too slowly or not at all. People inherit one TPMT copy from each parent; two low-function copies usually cause TPMT deficiency, while one changed copy often leads to reduced activity rather than complete deficiency. For many, this can mean a much higher risk of dangerously low blood counts if standard doses are used. Because the genetic link is well established, blood testing or genetic testing for thiopurine s-methyltransferase deficiency is often used before treatment to help choose a safer dose or a different drug.
Is Thiopurine s-methyltransferase deficiency genetic?
Genetics are central to thiopurine S-methyltransferase deficiency. Changes in the TPMT gene largely determine how much enzyme your body makes, so inherited variants strongly affect who develops it and how they respond to thiopurine medicines.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal and common part of human biology across the general population. Most do not have a direct effect on health and simply reflect the natural differences seen among people. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, however, a single well-understood variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
If you need treatment with medicines such as azathioprine, mercaptopurine, or thioguanine, thiopurine S-methyltransferase deficiency can make a standard dose too strong for your body. This inherited difference means thiopurine drugs are broken down more slowly, so the medicine can build up and raise the risk of serious side effects, especially very low blood counts, infections, and liver problems. Genetic testing can sometimes identify how your body handles these medicines before treatment starts, which helps your care team choose a much lower dose or avoid the drug altogether. Many living with thiopurine S-methyltransferase deficiency have one changed copy of the gene and may still use a thiopurine with careful dose adjustment, while those with two changed copies usually need a different treatment plan. Doctors may also check for other genetic changes linked to thiopurine side effects, because more than one gene can affect safety. Even after genetic testing before thiopurine treatment, regular blood tests are still important to make sure treatment stays safe for people with thiopurine S-methyltransferase deficiency.
Interactions with other conditions
Thiopurine s-methyltransferase deficiency usually matters most when someone needs certain medicines for inflammatory bowel disease, leukemia, or autoimmune conditions, because their body may not break these drugs down safely. For many, this can mean that a standard dose of azathioprine, mercaptopurine, or thioguanine can build up and seriously damage the bone marrow, leading to infections, easy bruising, or severe tiredness. Doctors call it a comorbidity when two conditions occur together, and in this case the main concern is the combination of TPMT deficiency with an illness that is treated with a thiopurine drug. Someone might notice their symptoms flare when another condition is active, but with TPMT deficiency, problems are often caused more by the medicine than by the other disease itself. This is why people with TPMT deficiency who also have Crohn’s disease, ulcerative colitis, acute lymphoblastic leukemia, or certain immune conditions usually need dose changes or a different treatment plan. If you are wondering about the early symptoms of thiopurine s-methyltransferase deficiency, many people do not notice anything until they start one of these medicines and then develop side effects that need urgent medical attention.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Thiopurine s-methyltransferase deficiency?
Thiopurine S-methyltransferase deficiency usually does not cause symptoms on its own, so when problems happen after medicines like azathioprine or mercaptopurine, doctors also think about another inherited sensitivity to the same drugs called NUDT15 deficiency, as well as other causes of very low blood counts. These can include serious viral infections, vitamin B12 or folate deficiency, bone marrow disorders such as aplastic anemia, and blood cancers like leukemia, because all can lead to tiredness, mouth sores, frequent infections, or easy bruising.
History
Long before this condition had a formal name, doctors noticed that a small number of people became dangerously unwell after taking standard doses of certain medicines used for leukemia, inflammatory bowel disease, and autoimmune conditions. Instead of getting the expected benefit, they could develop severe side effects, especially very low blood counts. Those puzzling reactions led researchers to look more closely at how the body processes these drugs, which is how thiopurine s-methyltransferase deficiency came into medical focus.
In the 1970s and 1980s, scientists showed that people differ naturally in the activity of an enzyme called thiopurine S-methyltransferase, often shortened to TPMT. Some had normal activity, some had intermediate activity, and a small group had very little or none. In recent decades, awareness has grown as this difference was linked to the risk of serious toxicity from thiopurine medicines such as azathioprine, mercaptopurine, and thioguanine. This helped explain why one person could do well on treatment while another might become ill even on what looked like a usual dose.
As the evidence became stronger, thiopurine s-methyltransferase deficiency moved from being a laboratory finding to something that directly changed patient care. Hospitals and clinics increasingly began using blood tests or genetic testing for thiopurine s-methyltransferase deficiency before azathioprine treatment or before similar medicines were prescribed. That shift made treatment safer, because doses could be adjusted or different medicines chosen when needed.
Today, the history of thiopurine s-methyltransferase deficiency is closely tied to the wider story of personalized medicine. Rather than assuming everyone handles a drug in the same way, doctors now know that the body’s chemistry can vary a lot from one person to another. For many living with conditions that require thiopurine drugs, that history has real everyday value: it can mean fewer unexpected side effects, closer monitoring early on, and a treatment plan that better fits how their body works.